Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
A diagnosis of primary sclerosing cholangitis (PSC) has been associated with increased risk of hepatobiliary cancers, colorectal cancer and all-cause mortality in several studies, while associations with cardiovascular disease have been inconsistent. We conducted a systematic review and meta-analysis of published cohort studies on the topic to summarize these associations. PubMed and Embase databases were searched up to January 13th, 2020. Cohort studies on PSC and risk of cancer, cardiovascular disease, or mortality were included. Summary relative risks (RRs) and 95% confidence intervals (95% CIs) were estimated using random effects models. The summary RR (95% CI) comparing persons with PSC to persons without PSC was 584.37 (269.42–1267.51, I 2 = 89%, n = 4) for cholangiocarcinoma (CCA), 155.54 (125.34–193.02, I 2 = 0%, n = 3) for hepatobiliary cancer, 30.22 (11.99–76.17, I 2 = 0%, n = 2) for liver cancer, 16.92 (8.73–32.78, I 2 = 88%, n = 4) for gastrointestinal cancer, 7.56 (2.42–23.62, I 2 = 0%, n = 3) for pancreatic cancer, 6.10 (4.19–8.87, I 2 = 14%, n = 7) for colorectal cancer (CRC), 4.13 (2.99–5.71, I 2 = 80%, n = 5) for total cancer, 3.55 (2.94–4.28, I 2 = 46%, n = 5) for all-cause mortality, and 1.57 (0.25–9.69, I 2 = 79%, n = 2) for cardiovascular disease. Strong positive associations were observed between PSC and risk of CCA, hepatobiliary cancer, liver cancer, gastrointestinal cancer, pancreatic cancer, CRC, total cancer, and all-cause mortality, but not for cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People with PSC are at increased risk of developing hepatobiliary cancer, particularly CCA, for which the risk is increased 161-398-fold compared to that in the general population.5,7,285,286”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [286]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
(2014) · Medical Entomology and Zoology · Cited by 17,633
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Herman, J. G., Merlo, A. U., Mao, L., Lapidus, R. G., Issa, J. J., Davidson, N. E., Sidransky, D., & Baylin, S. B. (1995) · PubMed · Cited by 1,341
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
Cited by
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Shen, B., Abreu, M. T., Cohen, E. R., Farraye, F. A., Fischer, M., Feuerstadt, P., Kapur, S., Ko, H. M., Kochhar, G. S., Liu, X., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.08.034 · Cited by 54
New epidemiologic trends in cholangiocarcinoma
Pascale, A., Rosmorduc, O., & Duclos‐Vallée, J. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102223 · Cited by 53
National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
Dar, F. S., Abbas, Z., Ahmed, I., Atique, M., Aujla, U. I., Azeemuddin, M., Aziz, Z., Bhatti, A. B. H., Bangash, T. A., Butt, A. S., et al. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i9.1018 · Cited by 54
“While surgical resection remains the primary treatment for hCCA[81,153], a significant majority present with irresectable disease due to extensive biliary and vascular involvement at the hepatic hilus and underlying parenchymal liver disease such as PSC[81,153].”
InfluentialAge trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study
Rahman, R., Ludvigsson, J. F., von Seth, E., Lagergren, J., Bergquist, A. M., & Radkiewicz, C. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.032 · Cited by 38
Metadata
- Authors
- Aune, D., Sen, A., Norat, T., Riboli, E., & Folseraas, T.
- Affiliations
- Oslo University Hospital (NO)
- Norwegian University of Science and Technology (NO)
- Imperial College London (GB)
- Corresponding author
- Aune, Dagfinn
- Venue
- Scientific Reports
- Published
- 2021-05-20
- Volume
- 11
- Issue
- 1
- Pages
- 10646-10646
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC8137938
- OpenAlex
- W3161880169
- Cited by
- 40
- References
- 48
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 12 · 2023: 7 · 2022: 6 · 2021: 2
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- Raagholtstiftelsen
- Helse Sør-Øst RHF (2017076)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- primary sclerosing cholangitis, cholangiocarcinoma, hepatobiliary cancer, colorectal cancer, pancreatic cancer, liver cancer, gastrointestinal cancer, all-cause mortality, cardiovascular disease, cancer risk, mortality risk, bile duct diseases, inflammatory bowel disease, inflammatory myofibroblastic tumor
- MeSH terms
- Cardiovascular Diseases, Humans, Neoplasms, Risk, Risk Factors, Cholangitis, Sclerosing, Cohort Studies, Confidence Intervals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies. https://app.cochat.ai/papers/10.1038/s41598-021-90175-w
- The paper
- Aune, D., Sen, A., Norat, T., Riboli, E., & Folseraas, T. (2021). Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies. Scientific Reports. https://doi.org/10.1038/s41598-021-90175-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.